Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Follow-Up Questions
What is the price performance of CKDXF stock?
The current price of CKDXF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Opthea Ltd?
Opthea Ltd belongs to Biotechnology industry and the sector is Health Care
What is Opthea Ltd market cap?
Opthea Ltd's current market cap is $0
Is Opthea Ltd a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Opthea Ltd, including 0 strong buy, 1 buy, 3 hold, 4 sell, and 0 strong sell
